Cardiol Therapeutics Inc. (CRDL.TO)
| Previous Close | 2.2500 |
| Open | 2.3000 |
| Bid | 2.3600 x 0 |
| Ask | 2.3900 x 0 |
| Day's Range | 2.2200 - 2.4600 |
| 52 Week Range | 1.9700 - 6.1900 |
| Volume | |
| Avg. Volume | 316,753 |
| Market Cap | 140.533M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | Aug. 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.66 |
- Newsfile
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Ridker, MD, MPH, Bruce McManus, PhD, MD, and Joseph A. Hill, MD, PhD, to its Scientific Advisory Board (SAB). "We are pleased to welcome distinguished th
- Newsfile
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the "Offering") of 16,350,000 units of the Company (the "Units") at a price to the public of US$3.07 per Unit for gross proceeds of US$50,194,500, before
- Simply Wall St.
What You Need To Know About Cardiol Therapeutics Inc.'s (TSE:CRDL) Investor Composition
The big shareholder groups in Cardiol Therapeutics Inc. ( TSE:CRDL ) have power over the company. Large companies...
